Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
- PMID: 8382646
- DOI: 10.1016/0016-5085(93)91025-d
Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
Abstract
Background: Interferon alfa is effective for controlling disease activity in chronic hepatitis C. However, many responders suffer relapse after cessation of therapy. In the present study, the serum concentration of hepatitis C virus RNA was correlated with a sustained response to interferon therapy.
Methods: Fifty-three patients with chronic hepatitis C received a 26-week course of interferon alfa. Hepatitis C virus RNA was quantitated in serum at the beginning and end of treatment using a competitive assay that combined reverse transcription and polymerase chain reaction.
Results: In long-term responders, whose alanine aminotransferase levels remained within the normal range during the 24 weeks after therapy, the titer of viral RNA (logarithmic transformed copy numbers per milliliter of serum) before therapy (7.1 +/- 1.2) was significantly lower (P < 0.001) than that of short-term responders (8.3 +/- 0.5) who had a relapse within the 24 weeks after therapy and nonresponders (8.1 +/- 0.4). Multivariate multiple logistic regression showed that the titer of viral RNA before therapy was the strongest independent predictor of a sustained response to interferon-alfa therapy (P = 0.002).
Conclusions: The titer of hepatitis C virus RNA is the most important factor influencing the sustained response to interferon treatment.
Similar articles
-
Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.Ann Intern Med. 1995 Apr 15;122(8):586-91. doi: 10.7326/0003-4819-122-8-199504150-00005. Ann Intern Med. 1995. PMID: 7887552
-
Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon.Hepatology. 1994 Jun;19(6):1342-6. Hepatology. 1994. PMID: 8188165 Clinical Trial.
-
Predictive factors for beneficial response to interferon-alfa therapy in chronic hepatitis C.Korean J Intern Med. 1995 Jul;10(2):94-102. doi: 10.3904/kjim.1995.10.2.94. Korean J Intern Med. 1995. PMID: 7495780 Free PMC article. Clinical Trial.
-
Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.Hepatology. 1997 Sep;26(3 Suppl 1):101S-107S. doi: 10.1002/hep.510260718. Hepatology. 1997. PMID: 9305673 Review.
-
Treatment of HCV liver disease by recombinant interferon alpha.Nephrol Dial Transplant. 1996;11 Suppl 4:56-7. doi: 10.1093/ndt/11.supp4.56. Nephrol Dial Transplant. 1996. PMID: 8918757 Review.
Cited by
-
Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus-related chronic liver disease.World J Gastroenterol. 2005 Jul 7;11(25):3962-5. doi: 10.3748/wjg.v11.i25.3962. World J Gastroenterol. 2005. PMID: 15991303 Free PMC article.
-
Hepatitis C: diagnosis and treatment.J Gen Intern Med. 1995 May;10(5):273-82. doi: 10.1007/BF02599887. J Gen Intern Med. 1995. PMID: 7542329 Review. No abstract available.
-
Relationship between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections.Dig Dis Sci. 1996 Oct;41(10):1925-32. doi: 10.1007/BF02093591. Dig Dis Sci. 1996. PMID: 8888702
-
Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus.J Gastroenterol. 1997 Apr;32(2):211-5. doi: 10.1007/BF02936370. J Gastroenterol. 1997. PMID: 9085170
-
Evaluation of quantitative PCR and branched-chain DNA assay for detection of hepatitis B virus DNA in sera from hepatocellular carcinoma and liver transplant patients.J Clin Microbiol. 2000 May;38(5):1977-80. doi: 10.1128/JCM.38.5.1977-1980.2000. J Clin Microbiol. 2000. PMID: 10790133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical